Jack Randall Munn, Adulterating Drug, Texas 2017

Related Federal Cases

Juan Francisco Saenz-Tamez, Texas Drug Trafficking, Beaumont TX, 2023 · Oklahoma
US Justice Department, Drug and Arms Trafficking, Washington D.C., … · New York
Tren de Aragua Leaders Unsealed, Terror Cartel Crimes, Texas, 2023 · New York
Eduardo Ravelo, Racketeering Conspiracy, Texas 2013 · Oklahoma
Pam Bondi, Money Laundering, Texas, 2023 · Texas

Table of Contents

Pharmacist in Texas Admits to Adulterating Drug Used in Cataract Surgeries

A Texas pharmacist has pleaded guilty to one count of adulterating a drug that was used in cataract surgeries.

Jack Randall Munn, 71, of Dallas, a licensed pharmacist and former owner of Guardian Pharmacy Services (Guardian), a Dallas pharmacy, oversaw the compounding of the drug for two outpatient Dallas surgical centers in 2016 and 2017. The drug, a combination of an antibiotic and a steroid, contained an excessive amount of an inactive ingredient that can damage sensitive eye tissue.

At the time of the events described in court documents, Munn represented to the surgical centers that Guardian could compound the drug in a manner safe for injection into patients’ eyes. However, the drug made by Guardian contained an excessive amount of the inactive ingredient, causing its purity and quality to fall below that which it was represented to possess.

Munn pleaded guilty to one misdemeanor count of distributing an adulterated drug in violation of the Federal Food Drug and Cosmetic Act. He is scheduled to be sentenced on February 3, 2022 and faces a maximum penalty of one year in prison and a fine of up to $100,000.

The U.S. Food and Drug Administration’s (FDA) Office of Criminal Investigations investigated the case. Assistant Director John Claud, Senior Trial Counsel David A. Frank and Trial Attorney Sarah Williams of the Civil Division’s Consumer Protection Branch are prosecuting the case.

Munn’s case is a stark reminder of the importance of ensuring the quality and safety of medications used in medical procedures. The FDA will continue to work tirelessly to protect the public from adulterated and misbranded drugs.